Rilzabrutinib is a covalent, reversible BTK inhibitor with multiple mechanisms targeting key immune thrombocytopenia (ITP) disease pathophysiology. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg bid (n=133) vs placebo (n=69) for 24 weeks. At baseline overall, median age was 47 years (range, 18-80), 63% female, 7.
View Article and Find Full Text PDFMetastatic young-onset colorectal cancer (yo-CRC) is a distinct and aggressive disease subtype that is becoming increasingly prevalent worldwide with Australia leading the world in this trend. This article provides an evidence-based perspective, through the prism of authors' personal experience, to craft an effective pathway not only to deliver improved outcomes for the patients but also to reduce disparities and foster collaboration amongst the cancer-treating community and indeed patients. It highlights an opportunity to re-define, re-design, and create a model that is rewarding to patients and cancer-treating community.
View Article and Find Full Text PDFObjectives: This study explores the extent and nature of compounding practices, and the relevant experiences and opinions of pharmacists within Australian community pharmacies.
Methods: A cross-sectional observational study was conducted using a self-administered survey that was emailed to 3349 Australian community pharmacies. The survey collected information on the extent and nature of compounding, as well as the experiences and opinions of pharmacists, using Likert scales and free-text responses.
Objective: To determine whether readily available patient, ultrasound and treatment outcome data can be used to develop, validate and externally test two machine learning (ML) models for predicting the success of expectant and medical management of miscarriage respectively.
Methods: A retrospective, multi-site study of patients opting for expectant or medical management of miscarriage was undertaken. A total of 1075 patients across two hospital early pregnancy units were eligible for inclusion.
J Thromb Haemost
February 2025
Background: It is widely accepted that autoantibodies directed against platelet glycoproteins (GP) are a major pathophysiological mechanism in immune thrombocytopenia (ITP), but little clinical data is available demonstrating an association between platelet antibodies and platelet counts.
Objectives: We hypothesized that if platelet antibodies are clinically relevant, number of targeted glycoproteins and antibody concentration should be associated with the extent of thrombocytopenia.
Methods: Platelet antibodies were identified in a direct, GP-specific test that detects antibodies against GP IIb/IIIa and GP Ib/IX.